The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
Open accessAbstract
Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mortality. Up to the end of 1998, 102,691 men have been randomized to the intervention arm and 115,322 to the control arm (which represents 83% of the target sample size) from 7 European countries and 10 screening centers in the USA. The principal screening method at all centers is determination of serum prostate‐specific antigen (PSA). The PLCO trial and some European centers use also digital rectal examination (DRE) as an ancillary screening test. In the core age group (55–69 years), 3,362 of 32,486 men screened (10%) had a serum PSA concentration of 4 ng/ml or greater, which is 1 cut‐off for biopsy (performed in 84%). An additional 6% was referred for further assessment based on other criteria, with much less efficiency. Differences in PSA by country are largely attributable to the age structure of the study population. The mean age‐specific PSA levels are lower in the PLCO trial (1.64 ng/ml [in the age group 55–59 years], 1.80 [60–64 years] and 2.18 [65–69 years) than in the ERSPC trial (1.28–1.71 [55–59], 1.75–2.87 [60–64] and 2.48–3.06 [65–69 years]). Detection rates at the first screen in the ERSPC trial range from 11 to 42/1,000 men screened and reflect underlying differences in incidence rates and screening procedures. In centers with consent to randomization design, adherence in the screening arm is 91%, but less than half of the men in the target population are enrolled in the trial. In population‐based centers in which men were randomized prior to consent, all eligible subjects are enrolled, but only about two‐thirds of the men in the intervention arm undergo screening. Considerable progress has been made in both trials. Enrollment will be completed in 2001. A substantial number of early prostate cancers have been detected. The differences between countries seem to reflect both underlying prostate cancer incidence and screening policy. The trials have the power to show definitive results in 2005–2008. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
Population-based study of long-term survival in patients with clinically localised prostate cancer
Lu-Yao, G. L., & Yao, S.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09380-4 · Cited by 416
Jacobsen, S. J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530180039027 · Cited by 225
Essink-Bot, M.-L., de Koning, H. J., Nijs, H. G. T., Kirkels, W. J., van der Maas, P. J., & Schroder, F. H. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.925 · Cited by 174
Self-citationRecommended Prostate-Specific Antigen Testing Intervals for the Detection of Curable Prostate Cancer
Carter, H. B. (1997) · JAMA · doi:10.1001/jama.1997.03540420052029 · Cited by 167
World Health Statistics Annual, 1995.
(1997) · Biometrics · doi:10.2307/2533537 · Cited by 143
Kramer, B. S., Gohagan, J. K., Prorok, P. C., & Smart, C. R. (2010) · Cancer · doi:10.1002/cncr.2820710215 · Cited by 139
Self-citationProspective Evaluation Plan for Randomised Trials of Prostate Cancer Screening
Auvinen, A. P., RIETBERGEN, J. B. W., Denis, L., Schröder, F. H., Prorok, P. C., & for the International Prostate Cancer Screening Trial Evaluatio Group (1996) · Journal of Medical Screening · doi:10.1177/096914139600300211 · Cited by 103
Self-citation
Cited by
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Self-citationWeir, H. K. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg040 · Cited by 867
American Cancer Society Guidelines for the Early Detection of Cancer, 2006
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.1.11 · Cited by 639
Cancer incidence and mortality in France over the period 1980–2005
Belot, A., Grosclaude, P., Bossard, N., Jougla, E., Benhamou, E., Delafosse, P., Guizard, A.-V., Molinié, F., Danzon, A., Bara, S., et al. (2008) · Revue d'Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2008.03.117 · Cited by 546
Metadata
- Authors
- de Koning, H. J., Auvinen, A., Berenguer Sanchez, A., Calais da Silva, F., Ciatto, S., Denis, L., Gohagan, J. K., Hakama, M., Hugosson, J., Kranse, R., Nelen, V., Prorok, P. C., Schröder, F. H., & ERSPC and the PLCO Trials (the International Prostate Cancer Screening Trials Evaluation Group)
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2001-12-13
- Volume
- 97
- Issue
- 2
- Pages
- 237-244
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1998836416
- Cited by
- 285
- References
- 11
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. https://app.cochat.ai/papers/10.1002/ijc.1588
- The paper
- de Koning, H. J., Auvinen, A., Berenguer Sanchez, A., Calais da Silva, F., Ciatto, S., Denis, L., Gohagan, J. K., Hakama, M., Hugosson, J., Kranse, R., Nelen, V., Prorok, P. C., Schröder, F. H., & ERSPC and the PLCO Trials (the International Prostate Cancer Screening Trials Evaluation Group). (2002). Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. International Journal of Cancer. https://doi.org/10.1002/ijc.1588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.